Details

Project TitleExperimental Disease Model for Evaluation of the Protective Efficacy of Vaccines Against Equine Herpesvirus-1 Neurological Disease
Track Code1544
Short DescriptionNone
AbstractNone
 
Tagsdisease model; equine herpesvirus-1; horse; neurological disease; low pre-exposure level; EHV-1
 
Posted DateOct 5, 2017 9:15 AM

Key Advantages

  • May provide an equine model system and methods for the assessment of experimental vaccines
  • May provide a reproducible, neurologic disease model for equine herpesvirus myeloencephalopathy
  • May provide quantifiable risk factors for the post-exposure development of equine herpesvirus

Market Opportunities

The global veterinary vaccines market has been estimated to reach $19 million by 2020 at a CAGR of 9.42% during the forecast period from 2014 to 2020. The recent emergence of a new, high-mortality herpesviral neurological disease of horses has fueled concerns about the future economic prosperity of the U.S. horse industry.  Current vaccines on the market have become refractory. It has been posited that genetic changes in the viral agent with a concomitant increase in its virulence is resulting in the increase of incidence, morbidity and case fatality rates. Although efforts to develop a more effective second-generation vaccine are underway, current murine model systems have several drawbacks. There remains a need for an equine disease model to test the efficacy of such experimental vaccines. 

Technology Solution

Researchers at the University of Kentucky have developed a novel equine disease model and methods useful for evaluating and developing safe and effective vaccines against equine herpesvirus infections. The innovativeness of the invention is its discovery of the unique properties of both the experimental horse subjects and the challenge strain of herpesvirus that allows for reproduction of the neurological disease in a high proportion of virus-inoculated horses. Additionally, the inventors have provided methods for determining the quantifiable risk factors for the post-exposure development and a unique equine herpesvirue-1 vaccine. 

Commercialization Status

patent filed; active

Available Fields of Use

  •  Equine industry
  • Veterinary biologics companies

Inventors

Allen, George

Patent Number(s)

US9642908B2

UK OTC Contact

Eric Castlen, Associate Director, Office of Technology Commercialization

A141 ASTeCC Building, Lexington, KY 40508-0286

(859) 257-8211   eric.castlen@uky.edu